You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 6,555,066


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,555,066
Title: Apparatus for performing a platelet inhibition test
Abstract:An apparatus for performing a platelet inhibition test on a sample of blood is provided, comprising a plurality of test cells, the cells being adapted for receiving an aliquot portion of the sample, wherein each of the cells comprises an anticoagulant and a clotting activator, and wherein at least one of the cells further comprises a platelet inactivating agent, wherein a clotting time is determined for each of the aliquot portions, and wherein a relative clotting time for each of the aliquot portions comprising the platelet inhibitor is determined as compared to a reference clotting time for a cell containing no platelet inhibitor, wherein the relative clotting times for the cells are determinative of the platelet inhibition of the sample.
Inventor(s): Baugh; Robert F. (Parker, CO), Lane; Carole G. (Greenwood Village, CO), Wilson; Adrian C. (Denver, CO)
Assignee: Medtronic, Inc. (Minneapolis, MN)
Application Number:09/810,747
Patent Claims:1. An apparatus for performing a platelet inhibition test on a sample of blood, said apparatus comprising a cartridge having a plurality of test cells, said cells being adapted for receiving an aliquot portion of said sample, wherein each of said cells comprises an anticoagulant and an optimized amount of a contact activator to achieve clotting, and wherein at least one of said cells further comprises a platelet inactivating agent, wherein a clotting time is determined for each of said aliquot portions, and wherein a relative clotting time for each of said aliquot portions comprising the platelet inactivating agent is determined as compared to a reference clotting time for said at least one cell containing no platelet inactivating agent, wherein said relative clotting times in said cells are determinative of the platelet inhibition of said sample.

2. The apparatus of claim 1, wherein the anticoagulant is heparin.

3. The apparatus of claim 2, wherein the amount of heparin in each cell is between about 1 unit and about 4 units per milliliter of blood sample.

4. The apparatus of claim 1, wherein the contact activator is a particle having a negatively charged surface.

5. The apparatus of claim 4, wherein said contact activator is kaolin.

6. The apparatus of claim 5, wherein the amount of contact activator in each cell is between about 2 percent and about 15 percent.

7. The apparatus of claim 4, wherein said contact activator is diatomaceous earth.

8. The apparatus of claim 4, wherein said contact activator is powdered glass.

9. The apparatus of claim 4, wherein said contact activator is silica.

10. The apparatus of claim 1, wherein said platelet inactivating agent is selected from the group consisting of Abciximab, 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid, hydrochloride trihydrate, and acetylsalicylic acid.

11. An apparatus for performing a platelet inhibition test on a sample of blood, said apparatus comprising a plurality of test cells adapted for receiving an aliquot of said sample, wherein each of said cells comprises an anticoagulant and an optimized amount of a contact activator to achieve clotting, and wherein at least one of said cells further comprises a platelet inactivating agent.

12. The apparatus of claim 11, wherein the anticoagulant is heparin.

13. The apparatus of claim 12, wherein the amount of heparin in each cell is between about 1 unit and about 4 units per milliliter of blood sample.

14. The apparatus of claim 11, wherein the contact activator is a particle having a negatively charged surface.

15. The apparatus of claim 14, wherein said contact activator is kaolin.

16. The apparatus of claim 15, wherein the amount of contact activator in each cell is between about 2 percent and about 15 percent.

17. The apparatus of claim 14, wherein said contact activator is diatomaceous earth.

18. The apparatus of claim 14, wherein said contact activator is powdered glass.

19. The apparatus of claim 14, wherein said contact activator is silica.

20. The apparatus of claim 11, wherein said platelet inactivating agent is selected from the group consisting of Abciximab, 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid, hydrochloride trihydrate, and acetylsalicylic acid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.